50岁及以上人群三剂与四剂蜱传脑炎疫苗FSME-Immun基础免疫程序比较:单中心、开放标签、随机对照试验
单中心开放标签随机对照试验纳入200名蜱传脑炎未免疫的瑞典成人,50岁及以上者(n=150)随机分配至标准三剂程序(0-30-360天)或两种四剂程序(0-7-21-360天;0-30-90-360天),50岁以下者(n=50)采用标准三剂程序;第400天50岁及以上者三剂程序中和抗体几何平均滴度低于年轻组(41 vs 74,p<0.05),四剂0-7-21-360程序第400天滴度高于三剂程序(103 vs 41,p<0.01)。
要点
- 50岁及以上者标准三剂程序第400天抗体滴度低于50岁以下者(41 vs 74,p<0.05)。
- 四剂0-7-21-360程序第400天滴度高于三剂程序(103 vs 41,p<0.01)。
- 四剂0-30-90-360程序第400天与三剂程序无显著差异(63 vs 41,NS)。
核心结论
- 蜱传脑炎疫苗免疫应答随年龄增长而下降;四剂0-7-21-360程序可能对50岁及以上人群有益。
研究设计与样本
- 单中心、开放标签、随机对照试验,纳入200名蜱传脑炎未免疫的瑞典成人,50岁及以上者(n=150)随机分配至标准三剂程序(0-30-360天)或两种四剂程序(0-7-21-360天;0-30-90-360天),50岁以下者(n=50)采用标准三剂程序。
主要发现
- 第400天50岁及以上者标准三剂程序中和抗体几何平均滴度低于50岁以下者(41 vs 74,p<0.05)。
- 50岁及以上者四剂0-7-21-360程序第400天滴度高于标准三剂程序(103 vs 41,p<0.01),第60、120、360天亦较高。
- 50岁及以上者四剂0-30-90-360程序第400天滴度与标准三剂程序无显著差异(63 vs 41,NS)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: TBE vaccination failures among those past middle age have raised concern about immune response declining with age. We investigated immunogenicity of the TBE-vaccine FSME-Immun among those aged 50+ years using the standard three-dose primary series and alternative four-dose schedules. METHODS: In this single-centre, open-label, randomized controlled trial, 200 TBE-naive Swedish adults were given primary TBE vaccination with FSME-Immun. Those aged 50+ years (n = 150) were randomized to receive the standard three-dose (days 0-30-360) or one of two four-dose series (0-7-21-360; 0-30-90-360). For participants < 50 years (n = 50) the standard three-dose schedule was used. Titres of neutralizing antibodies were determined on days 0, 60, 120, 360, and 400. The main outcome was the log titre of TBE virus-specific neutralizing antibodies on day 400. RESULTS: The three-dose schedule yielded lower antibody titres among those aged 50+ years than the younger participants on day 400 (geometric mean titre 41 versus 74, p < 0.05). The older group showed higher titres for the four-dose 0-7-21-360 than the standard three-dose schedule both on day 400 (103 versus 41, p < 0.01; primary end point) and at the other testing points (days 60, 120, 360). Using the other four-dose schedule (0-30-90-360), no such difference was observed on day 400 (63 versus 41, NS). CONCLUSION: Immune response to the TBE vaccine declined with age. A four-dose schedule (0-7-21-360) may benefit those aged 50 years or older. This study is registered at ClinicalTrials.gov, NCT01361776.
引用
- Kantele A, Rombo L, Vene S, et al. Three-dose versus four-dose primary schedules for tick-borne encephalitis (TBE) vaccine FSME-immun for those aged 50 years or older: A single-centre, open-label, randomized controlled trial. Vaccine. 2022. PMID: 35101266. doi:10.1016/j.vaccine.2022.01.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。